Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2013

View Archived Issues

Disappointing results presented for linsitinib in phase II SCLC trial

Gender-specific modulation of hormone receptor activity to treat neurodegenerative disorders

Preclinical characteristics of uridine nucleotide prodrug IDX-30963 described

Cancer Research Technology and Nuevolution form collaboration to discover anticancer drug molecules

Ignyta completes merger and signs license agreement for tyrosine kinase inhibitors

Sanofi reflects on accomplishments of third quarter 2013

The Myelin Repair Foundation forms partnership with Bionure

Curemark begins rolling NDA submission for CM-AT

ND-654 and ND-630 evaluated for liver cancer and steatohepatitis

CureVac collaborates with the Cancer Research Institute and Ludwig Cancer Research

Roche discloses new CYP11B1/CPY11B2 inhibitors

Korean researchers prepare new DGAT1 inhibitors

Polyphor and Roche to develop therapeutic for multidrug-resistant bacterial infections

3pRNA RIG-I agonist displays activity against melanoma

Hookipa Biotech closes series B financing round to support product development

siRNA therapeutics targeted for AIP

RNA-based adjuvant demonstrates potent boosting in vivo

Shire provides topline results from pivotal phase III trials of Vyvanse in binge eating disorder

Researchers to conduct a phase I trial of a human monoclonal antibody for Hendra virus

First-in-human study of a therapeutic protein derived from CAP cells shows promise

RepliCel forms clinical advisory board to support the development of RCT-01

ImmunoGen discontinues IMGN-901 study in small-cell lung cancer

Endo Health Solutions to acquire Paladin Labs

Noven Pharmaceuticals launches Brisdelle in the U.S.

Bristol-Myers Squibb submits NDA in Japan for interferon- and ribavirin-free regimen for HCV

Gruenenthal patents new agents activating voltage-gated potassium channels

Glenmark Pharmaceuticals synthesizes novel MPGES-1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...